8 completed. 8 Phase 2, 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 8 |
| Phase 3 | 6 | Completed 6 |
Follow Contrave: new trials by email Literature Review of Contrave trials Research Report on Contrave
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a) Naltrexone and Bupropion (NB) medication, Placebo - Loss-of-Control Eating, Obesity/Overweight | Phase 2 / Phase 3 | Completed | Yale University | 24 | 2022-06-10 | 2026-08-26 |
| Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1) Naltrexone and Bupropion medication, Behavioral Weight Loss, Placebo - Loss-of-control Eating, Obesity/Overweight | Phase 2 / Phase 3 | Completed | Yale University | 92 | 2021-06-29 | 2026-08-26 |
| Adaptive Nutrition and Exercise Weight Loss (A-NEW) Study Contrave, Behavioral Weight Loss - Breast Cancer, Overweight or Obesity | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 53 | 2021-02-08 | 2025-03-06 |
| Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination, Placebo - Binge-Eating Disorder | Phase 2 / Phase 3 | Completed | Yale University | 89 | 2018-04-17 | 2024-04-03 |
| Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment Cognitive-Behavioral Therapy (CBT), NB Medication (on-going from acute treatment) - Binge-Eating Disorder, Obesity | Phase 2 / Phase 3 | Completed | Yale University | 31 | 2017-09-05 | 2024-02-01 |
| Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy NB medication (Naltrexone Bupropion combination), Placebo - Binge-Eating Disorder, Obesity | Phase 2 / Phase 3 | Completed | Yale University | 68 | 2017-08-28 | 2024-02-02 |
| Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment NB medication (Naltrexone Bupropion combination), Behavioral Weight Loss (BWL) counseling, Placebo - Binge-eating Disorder, Obesity | Phase 2 / Phase 3 | Completed | Yale University | 136 | 2017-02-27 | 2023-03-08 |
| A Study of Naltrexone SR/ Bupropion SR in Overweight and Obese Subjects Who Are Nicotine-Dependent NB32, Ancillary therapy - Nicotine Dependence, Overweight | Phase 2 | Completed | Orexigen Therapeutics, Inc | 30 | 2007-10-01 | 2012-11-02 |
Obesity (7) · Binge-Eating Disorder (4) · Overweight (4) · Breast Neoplasms (1) · Tobacco Use Disorder (1)
Yale University (6) · Orexigen Therapeutics, Inc (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
United States (8)
Carlos M Grilo, PhD (3) · Carlos Grilo, PhD (1) · Jennifer Sheng (1) · Nader Oskooilar, M.D., Ph.D. (1) · Sherry McKee, PhD (1) · Valentina Ivezaj, Ph.D. (1)
R01DK049587 (3), R01DK126637 (2), R01DK112771 (1)